Apremilast 30 mg

DRUG3 trials

Sponsors

Amgen

Conditions

Plaque-type PsoriasisPsoriasisPsoriatic ArthritisRheumatoid Arthritis

Phase 2

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

CompletedNCT00773734

AmgenPlaque-type Psoriasis, Psoriasis

Start: 2008-09-01End: 2015-05-20Updated: 2020-05-07

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

TerminatedNCT01285310

AmgenRheumatoid Arthritis

Start: 2010-12-09End: 2012-09-10Updated: 2020-05-08

Phase 3

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

CompletedNCT01925768

AmgenPsoriatic Arthritis

Start: 2013-09-04End: 2016-11-17Updated: 2020-05-12

Related Papers

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

American Journal of Clinical Dermatology2023-06-1440 citations

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Annals of the Rheumatic Diseases2018-04-1288 citations

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

2013-05-1052 citations

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

2012-06-29191 citations